Clinical Report: Evaluating the Antitumor Effects of Tricyclic Medications

Overview

This study evaluates the antitumor effects of chlorpromazine, amitriptyline, and imipramine across breast cancer, neuroblastoma, and melanoma.

Background

Tricyclic medications, traditionally used for psychiatric conditions, have shown potential in cancer treatment due to their antitumorigenic properties. This study aims to clarify the comparative antitumor effects of these drugs.

Data Highlights

Key Findings

• Chlorpromazine exhibited the strongest antitumor effects across MDA-MB-231 and SH-SY5Y cell lines.
• Amitriptyline showed intermediate antitumor effects in all tested cell lines.
• Imipramine had significant effects only on MDA-MB-231 xenografts.
• All three drugs failed to inhibit tumor growth in A375 xenografts.
• Wound-healing assays indicated that all drugs impaired migration in MDA-MB-231 and SH-SY5Y cells.

Clinical Implications

The differential antitumor effects of tricyclic medications could guide their potential repurposing for cancer treatment. Clinicians should consider the specific cancer type when evaluating these drugs for therapeutic use.

Conclusion

This study highlights the antitumorigenic potential of chlorpromazine, amitriptyline, and imipramine.

Related Resources & Content

1. Journal of Gastroenterology, 2012 -- Impact of Serotonergic Psychoactive Medications on Gastrointestinal Function and Symptoms in Functional GI Disorders
2. Nature Medicine, 2026 -- Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial
3. The ASCO Post, 2015 -- APF530 Superior to Ondansetron in Preventing Chemotherapy-Induced Nausea or Vomiting
4. Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. P11.60.A RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS - PMC
6. The ASCO Post — Telotristat Ethyl: A Novel Therapy for Carcinoid Syndrome—Not a Panacea but a Step in the Right Direction
7. Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
8. P11.60.A RACTAC TRIAL: PHASE II MULTICENTRIC ITALIAN TRIAL ON REPOSITIONING OF THE ANTIPSYCHOTIC DRUG CHLORPROMAZINE AND ITS COMBINATION WITH TEMOZOLOMIDE IN MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS - PMC
9. Imipramine before Surgery in Treating Patients with Previously Untreated Invasive Breast Cancer - NCI